NeoGenomics to Present Eight Abstracts at ASCO 2026 Covering MRD, NGS, and Real-World Evidence (ir.neogenomics.com)

• Eight abstracts at ASCO 2026 covering MRD, NGS coverage, and new biomarkers
• Collaboration with MD Anderson on RaDaR® ST in colorectal cancer
• Development of a low-sample-input AML MRD flow assay with higher sensitivity
• Updated company mission and tagline: 'Answers are in our DNA'

"NeoGenomics announced it will present eight scientific abstracts at the 2026 ASCO Annual Meeting. The presentations cover advances in molecular residual disease (MRD) detection via RaDaR® ST, real-world impact of NGS insurance coverage gaps, and new biomarkers for targeted therapies. The company is also developing a low-sample-input AML MRD flow assay for higher sensitivity and faster turnaround. NeoGenomics updated its mission and vision, emphasizing personalized cancer care."